Please login to the form below

Not currently logged in

Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021

At 30 months post-treatment, 26.9% of Venclyxto-treated patients had undetectable minimal residual disease

Roche has revealed new data from various late-stage trials evaluating its AbbVie-partnered BCL-2 inhibitor Venclyxto, including four-year follow-up analysis from the phase 3 CLL14 study. 

The four-year follow-up data includes a post-hoc analysis of investigator-assessed progression-free survival (PFS), with a median follow-up of 52.4 months.

This analysis showed that the chemotherapy-free Venclyxto (venetoclax) plus Gazyvaro (obinutuzumab) regimen had an estimated PFS rate of 74% in previously untreated patients with chronic lymphocytic leukaemia (CLL) compared to 35% for Gazyvaro plus chlorambucil, three years after completion of a one-year fixed-duration treatment with the regimen.

On top of that, 30 months post-treatment, 26.9% of the Venclyxto-treated patients still had undetectable minimal residual disease (uMRD) compared with just 3.2% of those treated with Gazyvaro plus chlorambucil.

In another post-hoc analysis, this time of the phase 3 VIALE-3 study, acute myeloid leukaemia (AML) patients who achieved a composite complete remission and uMRD following treatment with Venclyxto and azacitidine had improved survival outcomes compared with those who were MRD-positive following treatment.

For the patients who achieved composite complete remission (CCR) and uMRD, a 94% overall survival rate was observed compared to 67.9% for those who did not achieve CCR and uMRD.

“The data from these Venclexta/Venclyxto combinations support our continued commitment to provide valuable therapeutic options for patients with hard-to-treat blood cancers,” said Levi Garraway, chief medical officer and head of global product development, Roche.

“[This] data also advances our understanding of minimal residual disease, which we believe is a useful endpoint that may help identify patients more quickly who are in need of additional treatment,” he added.

In May, the European Commission (EC) approved Venclyxto in combination with azacitidine and decitabine for the treatment of newly diagnosed acute myeloid leukaemia (AML) patients who can’t receive intensive chemotherapy.

The approval was supported by the VIALE-A study – in the trial, Venclyxto plus azacytidine reduced the risk of death by 34% compared to azacytidine alone, with a median overall survival of 14.7 months in the Venclyxto group compared to 9.6 months in the control group.

In the US, Venclyxto is approved as Venclexta in combination with azacitidine, decitabine, or low dose cytarabine for the treatment of newly diagnosed AML in adults aged 75 years and older, or who have comorbidities that prevent the use of intensive induction chemotherapy.

Article by
Lucy Parsons

14th June 2021

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....